Certara vs Oncodesign Services

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/certara/oncodesign-services

Category	Certara	Oncodesign Services
Listed site	cro	cro
Summary	Certara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.	Contract research organization specializing in drug discovery and preclinical services for oncology, inflammation, and infectious diseases since 1995.
Services	Biostatistics & Statistical Programming Data Management & eClinical Regulatory Affairs Medical Writing Computational & In-Silico Drug Discovery Translational Research Target Identification & Validation High-Throughput Screening Medicinal Chemistry In Vitro Pharmacology In Vitro ADME / DMPK Safety Pharmacology Genetic Toxicology Discovery Research In Vivo Efficacy Models In Vivo PK / PD Studies GLP Toxicology Preclinical In Vitro Studies Preclinical In Vivo Studies Bioanalysis LC-MS Bioanalysis (Small Molecule) Ligand-Binding Bioanalysis (Large Molecule) Phase I Clinical Trials Biomarker Assays Phase II Clinical Trials Phase III Clinical Trials Clinical Operations Phase IV / Post-Marketing US FDA Regulatory Strategy US FDA Regulatory Strategy EU EMA Regulatory Strategy EU EMA Regulatory Strategy Japan PMDA Regulatory Strategy Japan PMDA Regulatory Strategy China NMPA Regulatory Strategy China NMPA Regulatory Strategy Clinical Trial Services	Discovery Research Target Identification & Validation Medicinal Chemistry In Vitro Pharmacology In Vitro ADME / DMPK In Vivo PK / PD Studies In Vivo Efficacy Models Preclinical In Vivo Studies Specialized & Large-Animal Models Bioanalysis Immunogenicity Assays (ADA / NAb) Biomarker Assays Clinical Imaging Core Lab Oncology Specialty Services Immunology & Inflammation Services Virology Services GLP Toxicology Safety Pharmacology Translational Research Preclinical In Vitro Studies Regulatory Affairs LC-MS Bioanalysis (Small Molecule) High-Throughput Screening Genetic Toxicology Computational & In-Silico Drug Discovery Carcinogenicity Studies DART (Reproductive & Developmental Toxicology) Flow Cytometry Services Analytical Method Development & Validation ICH Stability Studies Ligand-Binding Bioanalysis (Large Molecule)
Modalities	Small Molecule Small Molecule Biologics (Monoclonal Antibodies) Biologics (Monoclonal Antibodies) Biologics (Other) Biologics (Other) Peptide Peptide Oligonucleotide Oligonucleotide mRNA mRNA Antibody-Drug Conjugate (ADC) Antibody-Drug Conjugate (ADC) Gene Therapy Gene Therapy Cell Therapy Cell Therapy Vaccine Vaccine	Small Molecule Biologics (Other) Antibody-Drug Conjugate (ADC) Radiopharmaceutical
Indications	Oncology Rare Disease Immunology Immunology Neurology Neurology Psychiatry Metabolic Metabolic Cardiovascular Cardiovascular Infectious Disease Infectious Disease Respiratory Respiratory Dermatology Dermatology Ophthalmology Ophthalmology Gastroenterology Gastroenterology Nephrology Nephrology Women's Health Women's Health	Oncology Immunology Infectious Disease Dermatology Gastroenterology Nephrology Metabolic Rare Disease Respiratory
Locations	Global network Global presence, 30 countries Global presence, Multiple, 30 countries, Global Global presence, Multiple, 30+ countries Global presence, Multiple, 30 countries, International Headquarters, Radnor, Pennsylvania, United States Global presence, 30 countries Global presence, 30+ countries	Headquarters, Dijon, Bourgogne-Franche-Comté, France Headquarters
Certifications	Data not yet provided.	Data not yet provided.
Reviews	Review summary appears after site-level review signal gate opens.	Review summary appears after site-level review signal gate opens.